Nervgen Pharma (NGEN) EPS (Basic) (2025 - 2026)
Nervgen Pharma (NGEN) posted quarterly EPS (Basic) of -$0.02 for Q1 2026, up 60.73% year-over-year from -$0.01 in Q1 2025, and up 60.73% quarter-over-quarter from -$0.04 in Q1 2025.
Nervgen Pharma (NGEN) EPS (Basic) (2025 - 2026) Analysis & Trends
Nervgen Pharma (NGEN) has reported EPS (Basic) for 2 consecutive years, with -$0.02 the latest figure, recorded in Q1 2026.
- In Q1 2026, EPS (Basic) rose 60.73% year-over-year to -$0.02; the TTM figure through Mar 2026 stood at -$0.05 (changed N/A YoY), while the FY2025 annual figure was -$0.44, down 69.62% from the prior year.
- EPS (Basic) improved to -$0.02 in Q1 2026 per NGEN's latest filing, from -$0.04 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$0.02 in Q1 2026 and bottomed at -$0.04 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.18 |
| 10 | Nervgen Pharma | 168.94 Mn | 168.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.02 |
| Mar 31, 2025 | -0.04 |